Select Page

Anti-Mouse CD279 (PD-1) SAFIRE Purified

This product is only available in the US
FP20582510
Antibody
100 μg

THIS ITEM HAS BEEN DISCONTINUED

DATA SHEET

The J43.1 monoclonal antibody specifically reacts with mouse CD279, also known as PD-1 (programmed death-1), a 50-55 kDa glycoprotein of the Ig superfamily. The PD-1 ligands, PD-L1 (B7-H1) and PD-L2 (B7-H2) are members of the B7 family. Pd-1 contains an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) and influences the peripheral tolerances and autoimmune diseases in mice. PD-1 is transiently expressed on CD4/CD8 thymocytes, it is upregulated in apoptotic cells, and it is expressed by activated myeloid and T and B cells.

The binding of PD-1 to its ligands is blocked by the J43 antibody, which also enhances contact hypersensitivity and exacerbates acute Graft-versus-host disease, Experimental autoimmune encephalomyelitis and NOD diabetes. PD-1 seems to downregulate the immune response, as the development of splenomegaly and breakdown of peripheral tolerance in PD-1 deficient mice suggests.

Application Notes: The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. It is recommended that the reagent be titrated for optimal performance for each application.

TargetPD-1
Product TypeAntibody
ApplicationFCM, FA, IHC, IP
ClonalityMonoclonal
ConjugateSAFIRE Purified
IsotypeIgG
Host SpeciesHamster
Species ReactivityMouse
FormulationPhosphate-buffered aqueous solution, ph7.2.
Research AreaAdaptive Immunity, Apoptosis, Flow Cytometry
Storage TemperatureThe product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/µg of the protein.
ProtocolsFCM, FA, IHC, IP
Clone NumberJ43.1
Concentration2.0 mg/mL
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
This product is only available in the US
FP20582510
Antibody
100 μg

THIS ITEM HAS BEEN DISCONTINUED

Related Content

SIGN UP